Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Culture
2.2. Culture Conditions
2.3. Use of Pharmacological Inhibitors of Cell Signaling
2.4. RNA Analysis
2.5. Protein Detection
2.5.1. Enzyme-Linked Immunosorbent Assay (ELISA)
2.5.2. Western Blot Analysis
2.5.3. AMPKα Over-Expression
2.5.4. Change in Cellular Free Fatty Acid (FFA)
2.5.5. Quantification and Statistical Analysis
3. Results
3.1. CYP2E1 but Not ADH EtOH Metabolism Alters FABP4 and Intracellular FFA Levels
3.2. Role of AMPKα in Regulating FABP4 Expression and Fatty Acid Accumulation
3.3. Role of Downstream AMPKα Effectors in Regulating FABP4 and Cellular Steatosis
3.3.1. Acetyl-CoA Carboxylase (ACC)
3.3.2. Lipin-1β
3.3.3. Sterol Regulatory-Element Binding Protein (SREBP-1c)
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- McKillop, I.H.; Schrum, L.W.; Thompson, K.J. Role of alcohol in the development and progression of hepatocellular carcinoma. Hepatic Oncol. 2016, 3, 29–43. [Google Scholar] [CrossRef] [PubMed]
- Subramaniyan, V.; Chakravarthi, S.; Jegasothy, R.; Seng, W.Y.; Fuloria, N.K.; Fuloria, S.; Hazarika, I.; Das, A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol. Rep. 2021, 8, 376–385. [Google Scholar] [CrossRef]
- Neuman, M.G.; French, S.W.; French, B.A.; Seitz, H.K.; Cohen, L.B.; Mueller, S.; Osna, N.A.; Kharbanda, K.K.; Seth, D.; Bautista, A.; et al. Alcoholic and non-alcoholic steatohepatitis. Exp. Mol. Pathol. 2014, 97, 492–510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eguchi, A.; Iwasa, M. The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases. Pharm. Res. 2021, 38, 89–95. [Google Scholar] [CrossRef] [PubMed]
- Thumser, A.E.; Moore, J.B.; Plant, N. Fatty acid binding proteins: Tissue-specific functions in health and disease. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 124–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thompson, K.J.; Austin, R.G.; Nazari, S.S.; Gersin, K.S.; Iannitti, D.A.; McKillop, I.H. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int. 2017, 38, 1074–1083. [Google Scholar] [CrossRef]
- Attal, N.; Sullivan, M.T.; Girardi, C.A.; Thompson, K.J.; McKillop, I.H. Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. Transl. Oncol. 2020, 14, 100975. [Google Scholar] [CrossRef]
- Rodríguez-Calvo, R.; Girona, J.; Alegret, J.M.; Bosquet, A.; Ibarretxe, D.; Masana, L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J. Endocrinol. 2017, 233, R173–R184. [Google Scholar] [CrossRef] [Green Version]
- McKillop, I.H.; Girardi, C.A.; Thompson, K.J. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell. Signal. 2019, 62, 109336. [Google Scholar] [CrossRef]
- Cederbaum, A.I. Alcohol Metabolism. Clin. Liver Dis. 2012, 16, 667–685. [Google Scholar] [CrossRef]
- Seitz, H.K. The role of cytochrome P4502E1 in the pathogenesis of alcoholic liver disease and carcinogenesis. Chem. Biol. Interact. 2020, 316, 108918. [Google Scholar] [CrossRef] [PubMed]
- You, M.; Jogasuria, A.; Taylor, C.; Wu, J. Sirtuin 1 signaling and alcoholic fatty liver disease. Hepatobiliary Surg. Nutr. 2015, 4, 88–100. [Google Scholar] [CrossRef] [PubMed]
- Ding, R.-B.; Bao, J.; Deng, C.-X. Emerging roles of SIRT1 in fatty liver diseases. Int. J. Biol. Sci. 2017, 13, 852–867. [Google Scholar] [CrossRef] [PubMed]
- Bai, J.; Cederbaum, A.I. Adenovirus-mediated Overexpression of Catalase in the Cytosolic or Mitochondrial Compartment Protects against Cytochrome P450 2E1-dependent Toxicity in HepG2 Cells. J. Biol. Chem. 2001, 276, 4315–4321. [Google Scholar] [CrossRef] [Green Version]
- Donohue, T.M.; Osna, N.A.; Clemens, D.L. Recombinant Hep G2 cells that express alcohol dehydrogenase and cytochrome P450 2E1 as a model of ethanol-elicited cytotoxicity. Int. J. Biochem. Cell Biol. 2006, 38, 92–101. [Google Scholar] [CrossRef]
- Osna, N.A.; White, R.L.; Krutik, V.M.; Wang, T.; Weinman, S.A.; Donohue, T.M. Proteasome Activation by Hepatitis C Core Protein Is Reversed by Ethanol-Induced Oxidative Stress. Gastroenterology 2008, 134, 2144–2152. [Google Scholar] [CrossRef] [Green Version]
- Attal, N.; Marrero, E.; Thompson, K.J.; McKillop, I.H. Cytochrome P450 2E1-dependent hepatic ethanol metabolism induces fatty acid-binding protein 4 and steatosis. Alcohol. Clin. Exp. Res. 2022, 46, 928–940. [Google Scholar] [CrossRef]
- Guo, J.; Fang, W.; Chen, X.; Lin, Y.; Hu, G.; Wei, J.; Zhang, X.; Yang, C.; Li, J. Upstream stimulating factor 1 suppresses autophagy and hepatic lipid droplet catabolism by activating mTOR. FEBS Lett. 2018, 592, 2725–2738. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Chen, Y.-T.; Hu, P.; Huang, W.-C. Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling. Mol. Cancer Ther. 2014, 13, 855–866. [Google Scholar] [CrossRef] [Green Version]
- Griffith, D.A.; Kung, D.W.; Esler, W.P.; Amor, P.A.; Bagley, S.W.; Beysen, C.; Carvajal-Gonzalez, S.; Doran, S.D.; Limberakis, C.; Mathiowetz, A.M.; et al. Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. J. Med. Chem. 2014, 57, 10512–10526. [Google Scholar] [CrossRef]
- Farah, B.L.; Sinha, R.A.; Wu, Y.; Singh, B.K.; Zhou, J.; Bay, B.-H.; Yen, P.M. β-Adrenergic Agonist and Antagonist Regulation of Autophagy in HepG2 Cells, Primary Mouse Hepatocytes, and Mouse Liver. PLoS ONE 2014, 9, e98155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rasineni, K.; Casey, C.A. Molecular mechanism of alcoholic fatty liver. Indian, J. Pharmacol. 2012, 44, 299–303. [Google Scholar] [CrossRef] [PubMed]
- Crabb, D.W.; Liangpunsakul, S. Alcohol and lipid metabolism. J. Gastroenterol. Hepatol. 2006, 21 (Suppl. S3), S56–S60. [Google Scholar] [CrossRef]
- You, M.; Arteel, G.E. Effect of ethanol on lipid metabolism. J. Hepatol. 2019, 70, 237–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sid, B.; Verrax, J.; Calderon, P.B. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochem. Pharmacol. 2013, 86, 200–209. [Google Scholar] [CrossRef]
- You, M.; Crabb, D.W. Recent Advances in Alcoholic Liver Disease II. Minireview: Molecular mechanisms of alcoholic fatty liver. Am. J. Physiol. Gastrointest Liver Physiol. 2004, 287, G1–G6. [Google Scholar] [CrossRef] [Green Version]
- Hu, M.; Wang, F.; Li, X.; Rogers, C.Q.; Liang, X.; Finck, B.N.; Mitra, M.S.; Zhang, R.; Mitchell, D.A.; You, M. Regulation of hepatic lipin-1 by ethanol: Role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology 2011, 55, 437–446. [Google Scholar] [CrossRef] [Green Version]
- Zeng, T.; Zhang, C.-L.; Song, F.-Y.; Zhao, X.-L.; Xie, K.-Q. CMZ Reversed Chronic Ethanol-Induced Disturbance of PPAR-α Possibly by Suppressing Oxidative Stress and PGC-1α Acetylation, and Activating the MAPK and GSK3β Pathway. PLoS ONE 2014, 9, e98658. [Google Scholar] [CrossRef]
- Chen, Y.-Y.; Zhang, C.-L.; Zhao, X.-L.; Xie, K.-Q.; Zeng, T. Inhibition of cytochrome P4502E1 by chlormethiazole attenuated acute ethanol-induced fatty liver. Chem. Interactions 2014, 222, 18–26. [Google Scholar] [CrossRef]
- Wang, X.; Sato, R.; Brown, M.S.; Hua, X.; Goldstein, J.L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994, 77, 53–62. [Google Scholar] [CrossRef]
- Edwards, P.A.; Tabor, D.; Kast, H.R.; Venkateswaran, A. Regulation of gene expression by SREBP and SCAP. Biochim. et Biophys. Acta (BBA)—Mol. Cell Biol. Lipids 2000, 1529, 103–113. [Google Scholar] [CrossRef]
- Brown, M.S.; Goldstein, J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 1999, 96, 11041–11048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.-J.; et al. AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice. Cell Metab. 2011, 13, 376–388. [Google Scholar] [CrossRef] [Green Version]
- Gillilan, R.E.; Ayers, S.; Noy, N. Structural Basis for Activation of Fatty Acid-binding Protein 4. J. Mol. Biol. 2007, 372, 1246–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nieman, K.M.; Kenny, H.A.; Penicka, C.V.; Ladanyi, A.; Buell-Gutbrod, R.; Zillhardt, M.R.; Romero, I.L.; Carey, M.S.; Mills, G.B.; Hotamisligil, G.S.; et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17, 1498–1503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herroon, M.K.; Rajagurubandara, E.; Hardaway, A.L.; Powell, K.; Turchick, A.; Feldmann, D.; Podgorski, I. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 2013, 4, 2108–2123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uehara, H.; Takahashi, T.; Oha, M.; Ogawa, H.; Izumi, K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int. J. Cancer 2014, 135, 2558–2568. [Google Scholar] [CrossRef]
- Uehara, H.; Kobayashi, T.; Matsumoto, M.; Watanabe, S.; Yoneda, A.; Yoshimi, B. Adipose tissue: Critical contributor to the development of prostate cancer. J. Med. Investig. 2018, 65, 9–17. [Google Scholar] [CrossRef] [Green Version]
- Zhong, C.-Q.; Zhang, X.-P.; Ma, N.; Zhang, E.-B.; Li, J.-J.; Jiang, Y.-B.; Gao, Y.-Z.; Yuan, Y.-M.; Lan, S.-Q.; Xie, D.; et al. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Med. 2018, 7, 2629–2640. [Google Scholar] [CrossRef]
- Martin, G.G.; Atshaves, B.P.; Huang, H.; McIntosh, A.L.; Williams, B.J.; Pai, P.-J.; Russell, D.H.; Kier, A.B.; Schroeder, F. Hepatic phenotype of liver fatty acid binding protein gene-ablated mice. Am. J. Physiol. Gastrointest Liver Physiol. 2009, 297, G1053–G1065. [Google Scholar] [CrossRef]
- Favretto, F.; Assfalg, M.; Gallo, M.; Cicero, D.O.; D’Onofrio, M.; Molinari, H. Ligand Binding Promiscuity of Human Liver Fatty Acid Binding Protein: Structural and Dynamic Insights from an Interaction Study with Glycocholate and Oleate. ChemBioChem 2013, 14, 1807–1819. [Google Scholar] [CrossRef] [PubMed]
- Nemecz, G.; Schroeder, F. Selective binding of cholesterol by recombinant fatty acid binding proteins. J. Biol. Chem. 1991, 266, 17180–17186. [Google Scholar] [CrossRef]
- Wang, X.Q.; Yang, K.; He, Y.S.; Lu, L.; Shen, W.F. Receptor Mediated Elevation in FABP4 Levels by Advanced Glycation End Products Induces Cholesterol and Triacylglycerol Accumulation in THP-1 Macrophages. Lipids 2011, 46, 479–486. [Google Scholar] [CrossRef] [PubMed]
- Carr, R.M.; Dhir, R.; Yin, X.; Agarwal, B.; Ahima, R.S. Temporal Effects of Ethanol Consumption on Energy Homeostasis, Hepatic Steatosis, and Insulin Sensitivity in Mice. Alcohol. Clin. Exp. Res. 2013, 37, 1091–1099. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raynard, B.; Balian, A.; Fallik, D.; Capron, F.; Bedossa, P.; Chaput, J.-C.; Naveau, S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35, 635–638. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Attal, N.; Marrero, E.; Thompson, K.J.; McKillop, I.H. Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism. Biology 2022, 11, 1613. https://doi.org/10.3390/biology11111613
Attal N, Marrero E, Thompson KJ, McKillop IH. Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism. Biology. 2022; 11(11):1613. https://doi.org/10.3390/biology11111613
Chicago/Turabian StyleAttal, Neha, Emilio Marrero, Kyle J. Thompson, and Iain H. McKillop. 2022. "Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism" Biology 11, no. 11: 1613. https://doi.org/10.3390/biology11111613